Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Quest Diagnostics › 869 DGX shares were withheld to cover taxes or exercise cost (CFO) Insider trades
Why it stands out Routine share withholding; mechanical by default.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Mar 2, 2026
Reporting period Not applicable
Filed with the SEC Mar 4, 2026 CFO Tax withholding
Context Classification tax withholding
Code F — shares delivered to pay exercise price or tax liability
Planned / mechanical clue Tax mechanics (code F)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001022079-26-000023
Filed / recorded
Mar 4, 2026, 9:39 PM UTC
Added to OQRO Oct 2, 2026, 12:28 PM UTC
Data quality Verified: identifiers matched exactly
Issuer QUEST DIAGNOSTICS INC
Reporting person Sam Samad
Officer title Executive Vice President & CFO
Table Non-derivative (Table I)
Transaction date Mar 2, 2026
Acquired / disposed Disposed (D)
Footnotes from the filing Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units.
Around the same time Insider filing
Traded Apr 1 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Federal contracts
VISN 6 reference lab testing and courier services - OY3
The Department of Veterans Affairs has committed $2.71M to Quest Diagnostics so far. It runs until Mar 31, 2027.
Insider filing
Traded Mar 9 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Apr 28, 2025 Congress Disclosed purchase of DGX — reported range $1,001 - $15,000 Jul 24, 2025 Congress Disclosed sale of DGX — reported range $1,001 - $15,000 Jan 12, 2026 Company filing · Form 8-K · Results, Reg FD Reported its results, and shared information with investors Feb 10, 2026 Company filing · Form 8-K · Results, Other news Reported its results, and reported other company news Feb 10, 2026 Insider Officer sold ~$1.16M of DGX shares in the open market Feb 13, 2026 Insider · 1 person Insiders: 5 sales (~$5.4M) Feb 19, 2026 Insider · 3 people Insiders: 3 sales (~$717K) Mar 2, 2026 Insider CEO sold ~$2.13M of DGX shares in the open market What came next Mar 3, 2026 Insider · 3 people Insiders: 3 sales (~$326K) Mar 4, 2026 Insider Officer sold ~$538K of DGX shares in the open market Mar 5, 2026 Insider · 3 people Insiders: 3 sales (~$2.5M) Mar 9, 2026 Company filing · Form 8-K · Executive change, Reg FD Changed a top executive or board member, and shared information with investors “On March 9, 2026, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director.”